Author’s response: understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study

We thank Professor Miller for his comments1 regarding our paper,2 in which we outline a novel approach to modelling repeated lung function measures in people with cystic fibrosis (CF) over long follow-up periods. We agree that it would be interesting to apply our methodology using alternative methods of expressing lung function across the age range, and reiterate that our approach can be usefully applied to any clinical outcome measured repeatedly over extended periods.

While the merits of different approaches are appreciated, we chose to model forced expiratory volume in 1 s as a percentage of predicted (%FEV1) for a number of reasons. First, %FEV1 is still currently recognised as a key outcome measure in CF3 as it is predictive of survival, and is currently an important criterion in international lung transplant guidelines.4 Second, %FEV1 has been modelled previously over long follow-up periods, across the paediatric and adult age range in CF using a random-intercept and slope approach,5 and we wanted to compare our method with this. Third, standardised %FEV1 was the most commonly collected outcome measure in the Danish CF registry.

While we agree that use of recently developed all-age equations, such as those published by Stanojevic3 or Quanjer7 would be advantageous in avoiding arbitrary breaks, for the purposes of this analysis, we adhered to the approach that is currently used in Denmark to facilitate comparisons with previously published data. Irrespective of the precise outcome used, our finding that the error in repeated measurements of %FEV1 within individuals is large (average within-person SD of 6 percentage points) remains valid. Furthermore, our approach provides more realistic estimates of the underlying lung-function trajectory of people with chronic lung disease, by acknowledging the imprecision in individual measurements over time, and the correlation structure of repeated measurements on the same individual, issues that have all too often been disregarded in the past.

David Taylor-Robinson,1 Margaret Whitehead,1 Finn Diderichsen,2 Hanne Vebert Olesen,2 Tania Pressler,3 Rosalind Smyth,3 Peter Diggle6
1Department of Public Health and Policy, University of Liverpool, Liverpool, UK
2Department of Social Medicine, University of Copenhagen, Copenhagen, Denmark
3Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark
4Cystic Fibrosis Center, Rigshospitalet, Copenhagen, Denmark
5Institute of Child Health, UCL, London, UK
6Institute of Infection and Global Health, University of Liverpool, Liverpool, UK

Correspondence to Dr David Taylor-Robinson,
Department of Public Health and Policy, University of Liverpool, Liverpool, UK; dctr@liv.ac.uk

Funding DTR is supported by an MRC Population Health Scientist Fellowship (G0802448).

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.


Published Online First 4 December 2012

http://dx.doi.org/10.1136/thoraxjnl-2012-202838
doi:10.1136/thoraxjnl-2012-202954

REFERENCES
1 Miller M. FEV1 decline in cystic fibrosis. Thorax 2012; doi:10.1136/thoraxjnl-2012-202838.

Author's response: understanding the natural progression in %FEV₁ decline in patients with cystic fibrosis: a longitudinal study

David Taylor-Robinson, Margaret Whitehead, Finn Diderichsen, Hanne Vebert Olesen, Tania Pressler, Rosalind Smyth and Peter Diggle

Thorax 2013 68: 294-295 originally published online December 4, 2012
doi: 10.1136/thoraxjnl-2012-202954

These include:

References
This article cites 5 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/68/3/294.2#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/